Hematological Disorders Resource Center

Click on the subcategory below to find drug monographs for that particular area.

Comparing ESAs for Anemia

Is one erythropoiesis-stimulating agent (ESA) superior to others for treating anemia in patients with chronic kidney disease (CKD)?

First-in-Class Tx for Rare Leukemia

The FDA has approved Blincyto (blinatumomab) for the treatment of relapsed or refractory Philadelphia chromosome-negative precursor B-cell acute lymphoblastic leukemia.

Erwinaze Approved for IV Route

Jazz Pharmaceuticals announced that the FDA has approved the IV administration of Erwinaze (asparaginase Erwinia chrysantheum).

Fast Tracked Sickle Cell Disease Agent

NKT Therapeutics announced that the Food and Drug Administration (FDA) has granted Fast Track designation to NKTT120 for the treatment of sickle cell disease.

Blood Type and Cognitive Impairment Risk

Blood group AB and higher factor VIII are associated with increased incidence of cognitive impairment.

New Velcade Indication

Millennium: The Takeda Oncology Company announced that the Food and Drug Administration (FDA) has approved Velcade (bortezomib) for the treatment of mantle cell lymphoma (MCL) in previously untreated patients.version of Eisai's Dacogen.

Bacon as Nosebleed Treatment?

Physicians at the Detroit Medical Center have been awarded a unique prize for an unconventional treatment – using bacon to stop an uncontrollable nosebleed in a 4-year-old with Glanzmann thrombasthenia.

Featured courses from mycme

The Brigham Board Review in Hematology and OncologyExternal web site

The Brigham Board Review in Hematology and Oncology offers expert preparation for your ABIM subspecialty ...

CME 42.00 Credits

Infectious Disease, Endocrine, Hematologic and Derm SystemsExternal web site

This module reviews all topics on the NCCPA examination blueprint relating to the Infectious Disease, ...

CME 6.25 Credits

Treating a Relapsed/Refractory 63-Year-Old Male With Emerging Agents in CLLExternal web site

This case will follow a patient from diagnosis through the third-line treatment decision. Optimal management ...

CME|CE 0.50 Credits

Sign Up for Free e-newsletters